0QDU Stock Overview
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.25 |
| 52 Week High | kr0.27 |
| 52 Week Low | kr0.20 |
| Beta | 1.05 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QDU | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | 1.1% |
| 1Y | n/a | -25.4% | 8.1% |
Return vs Industry: Insufficient data to determine how 0QDU performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0QDU performed against the UK Market.
Price Volatility
| 0QDU volatility | |
|---|---|
| 0QDU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QDU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QDU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 8 | Ellen Donnelly | abliva.com |
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| 0QDU fundamental statistics | |
|---|---|
| Market cap | kr157.39m |
| Earnings (TTM) | -kr95.51m |
| Revenue (TTM) | kr137.00k |
1,149x
P/S Ratio-1.6x
P/E RatioIs 0QDU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QDU income statement (TTM) | |
|---|---|
| Revenue | kr137.00k |
| Cost of Revenue | kr68.82m |
| Gross Profit | -kr68.68m |
| Other Expenses | kr26.83m |
| Earnings | -kr95.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -0.09 |
| Gross Margin | -50,132.85% |
| Net Profit Margin | -69,714.60% |
| Debt/Equity Ratio | 0% |
How did 0QDU perform over the long term?
See historical performance and comparison